LeMaitre Vascular

LMAT · NASDAQ

$83.40+$1.09 (+1.32%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $82.31

LMAT analyst rating

BuyConsensus of 4 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy3
Hold1
Underperform0
Sell0

12-month price target · 9 analysts

Average $109.14 (+30.9% upside)

Low: $81.81
Now: $83.40
High: $138.60

Upgrades and downgrades

The latest rating actions, newest first

LMAT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Aug 5, 2026	Maintains	Equal-Weight	$104.00 → $94.00	19%
Barrington Research	Jun 3, 2026	Maintains	Outperform	$120.00	44%
Barrington Research	May 6, 2026	Maintains	Outperform	$105.00 → $120.00	44%
Citizens	May 6, 2026	Maintains	Market Outperform	$118.00 → $127.00	36%
Wells Fargo	May 6, 2026	Maintains	Equal-Weight	$94.00 → $104.00	19%
Barrington Research	Feb 26, 2026	Maintains	Outperform	$95.00 → $105.00	44%
Roth Capital	Feb 26, 2026	Maintains	Buy	$108.00 → $117.00	48%
Wells Fargo	Feb 26, 2026	Maintains	Equal-Weight	$87.00 → $94.00	19%
Citizens	Feb 26, 2026	Maintains	Market Outperform	$113.00 → $118.00	36%
Barrington Research	Feb 20, 2026	Maintains	Outperform	$95.00	44%

The case for and against

Updated Oct 15, 2026

Bull case

LeMaitre Vascular is well positioned by its durable pricing power, with an 8% pricing tailwind in the quarter, high-single-digit pricing trends historically, and price floors now applied to about 55% of products, supporting gross margin expansion to 72.7%. Its core growth engines are also strengthening, as 1Q26 revenue rose to $66.6 million with 10% organic growth, Artegraft surged 36% worldwide, and international regions such as EMEA and APAC grew 19.6% and 18.1%, respectively. The company’s outlook is further reinforced by disciplined execution, including operating-margin guidance near 29% for FY/26, adjusted EPS of $2.93 to $3.08, $367.2 million in cash and marketable securities, and strong free cash flow and buyback capacity.

Bear case

LeMaitre Vascular is facing a fragile risk/reward setup because nearly 40% of revenue has historically come from outside the U.S., where MDR compliance and securing/maintaining CE marks remain uncertain despite submissions to notified bodies. Its growth strategy also depends on acquiring limited, appropriately sized open vascular surgery targets, so a lack of deal execution could slow sales expansion. Operationally, tissue processing, preservation, and manufacturing disruptions could hurt results, even after Q1 revenue of $66.6 million rose 11% reported and 10% organically, underscoring that solid growth is still exposed to execution and regulatory pressure.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.